#USA #Boston #Huntington's Disease #Skyhawk Therapeutics #SKY-0515

Skyhawk Therapeutics Announces Encouraging Results for SKY-0515 in Huntington's Disease

Skyhawk Therapeutics, a clinical-stage biotechnology company, recently unveiled the one-year interim results from its Phase 1/2 clinical trial evaluating SKY-0515, a potential treatment for Huntington's disease (HD). This groundbreaking study reveals significant improvements in patients over the year and a promising safety profile for the experimental drug.

Key Findings

According to the latest data, patients treated with SKY-0515 showed a notable average improvement of +0.38 in their scores on the Composite Unified Huntington's Disease Rating Scale (cUHDRS). This is particularly striking given that a decline of -0.92 was anticipated based on existing data of naturally progressing HD patients.

Furthermore, patients receiving a 9 mg dose of SKY-0515 experienced a substantial 69% reduction in mutant huntingtin protein (mHTT) levels after twelve months. Notably, SKY-0515 has also positively affected the levels of PMS1, another critical protein linked to HD, displaying reductions of up to 26% in its RNA levels.

Clinical Implications

The results signal a pivotal advancement in the management of Huntington's disease, which remains a challenging neurodegenerative disorder with no approved disease-modifying treatments currently available. Phillip Sharp, a Nobel Prize laureate and member of Skyhawk's scientific advisory board, highlighted the potential of RNA modulation capabilities that SKY-0515 offers to patients worldwide.

Bill Haney, co-founder and CEO of Skyhawk Therapeutics, expressed optimism about the implications of these clinical results, stating that they open up the horizon for potential long-term benefits to patients suffering from Huntington's Disease. The distinct separation in clinical outcomes compared to expected disease progression indicates that SKY-0515 may exhibit durable effects.

Additionally, the study has recruited over 175 patients across both the ongoing Phase 1/2 trial and the pivotal Phase 2/3 FALCON-HD study, with extended recruitment to eight countries, including Australia and New Zealand.

Safety Profile

SKY-0515 showed excellent central nervous system exposure and was well-tolerated across all dose levels in the trial. Participants exhibited sustained, positive clinical improvements at three, six, nine, and twelve months post-treatment, suggesting that the drug is not only effective but also safe for long-term use.

Ed Wild, a leading neurologist at University College London, remarked on the encouraging nature of the results from the Phase 1/2 study, emphasizing that the substantial reduction in both mHTT and PMS1 positions SKY-0515 as a strong candidate for future therapeutic strategies against Huntington's.

The Road Ahead

Looking to the future, Skyhawk Therapeutics is eager to accelerate the development of SKY-0515 following the early conclusion of patient recruitment for its pivotal FALCON-HD study. The company's commitment is to develop and provide an orally administered treatment option for Huntington's that could fundamentally change the landscape of disease management.

With the Phase 1/2 trial demonstrating sustained improvements over time, the results pave the way for further exploration of this innovative approach. The potential impact of SKY-0515 is a beacon of hope for individuals affected by Huntington's disease globally.

Skyhawk Therapeutics continues to strengthen its pipeline with new therapeutic candidates targeting rare neurological disorders, aiming to bring transformative therapies that can be administered conveniently from home. As this clinical story unfolds, the future looks promising for patients seeking effective treatments for historically devastating conditions.